Clinical trials: End-Stage Heart Failure
Alzheimer Disease, Late Onset, Stroke
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to implement the…
- Conditions
- Alzheimer Disease, Late Onset, Stroke, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT05407272
- Testing
- Health Education Manual, manual
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wen-Shiou Pan
Kidney Failure, Chronic, Heart Failure
Empagliflozin in ESKD - A Feasibility Study
The aim of this study is to learn about the safety of empagliflozin in dialysis patients as a preparation for a future large clinical trial.
- Trial name
- NCT05687058
- Testing
- Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Mississippi Medical Center
End-stage Renal Disease, Cardiorenal Syndrome
Cardiorenal Syndrome in End-Stage Kidney Disease
Cardiorenal Syndrome (CRS) is prevalent among end-stage renal disease (ESRD) patients. Recently, its prevalence is rising. There are several different clinical presentations of this syndrome.
- Conditions
- End-stage Renal Disease, Cardiorenal Syndrome, Heart Disease
- Trial name
- NCT02238093
- Where
- Israel
- Volunteers
- 270 people
- Sponsor
- Hillel Yaffe Medical Center
Infective Endocarditis, End Stage Renal Disease
Incidence of Infective Endocarditis in End Stage Renal Disease Patients on Hemodialysis by Transesophageal Echocardiography in Assuit University Hospital
1. To detect in more detail the incidence of infective endocarditis in patients with end stage renal disease (ESRD) on hemodialysis. 2.
- Trial name
- NCT05692089
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Heart Failure
Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement
The purpose of this study is to determine if the delivery of cells just after implantation of left ventricular assist device will help to improve the pumping function of your heart and minimize heart enlargement in the future.
- Trial name
- ASSURANCE (NCT00869024)
- Testing
- Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Minnesota
Heart Failure
Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy
Cardiac function may improve in patients with end-stage heart failure who receive long-term support with ventricular assist devices (VAD).
- Trial name
- NCT00402376
- Testing
- Pravastatin, Carvedilol, Perindopril, Biventricular assist device (Thoratec paracorporeal assist device)
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Heart Failure, Arrhythmia, Ventricular
Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure
CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM.
- Conditions
- Heart Failure, Arrhythmia, Ventricular, Cardiomyopathy Ischemic, Catheter Ablation
- Trial name
- CASTLE-VT (NCT06556485)
- Testing
- Catheter ablation, Medical therapy
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Heart and Diabetes Center North-Rhine Westfalia
Acute Coronary Syndrome, Chronic Kidney Disease
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
A 4 week-duration cross-over study on Ticagrelor and Clopidogrel for the Acute Coronary Syndrome (ACS) and Chronic Kidney Disease (CKD) subjects, focusing on the platelet inhibition and safety observation.
- Conditions
- Acute Coronary Syndrome, Chronic Kidney Disease, End-Stage Renal Disease
- Trial name
- APROVE-CKD (NCT02459288)
- Testing
- Clopidogrel first, Ticagrelor first
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Ping-Yen Liu
Cardiovascular Diseases, End Stage Renal Disease
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER…
- Conditions
- Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
- Trial name
- CARSK (NCT03674307)
- Testing
- No screening, Regular Screening
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 3,306 people
- Sponsor
- University of British Columbia
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Congestive Heart Failure
Peritoneal Dialysis in Congestive Heart Failure
Rationale: End-stage congestive heart failure is a serious invalidating condition with a poor prognosis and increasing incidence.
- Trial name
- PDinCHF (NCT01124227)
- Testing
- icodextrin
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Martini Hospital Groningen
End-stage Kidney Disease, Hemodialysis
Exercise and Cardiac Stunning During HD
The purpose of this study is to determine the effect of a 12-week cycling during hemodialysis program on hemodialysis-induced myocardial stunning in adult individuals receiving hemodialysis.
- Trial name
- NCT04877041
- Testing
- Intradialytic Cycling
- Where
- 6 sites in Australia, Canada
- Volunteers
- 111 people
- Sponsor
- University of Manitoba
End-stage Renal Disease, Hemodialysis
Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in HD Patients(EGESTUDY)
This study aims to investigate the effects of high flux dialyser use and ultra pure dialysate utilization on cardiovascular disease by evaluating cardiovascular morbidity and mortality, progression of carotid artery intima-media…
- Trial name
- NCT00295191
- Testing
- high-flux membrane, low-flux membrane, conventional dialysate
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 704 people
- Sponsor
- Ege University
End-Stage Renal Disease, Hemodialysis
Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis
The investigators hypothesize that an increase in the duration of dialysis session in thrice weekly center hemodialysis may provide better outcome, less morbidity, higher quality of life, lesser requirement of medications, and…
- Trial name
- NCT00413803
- Testing
- 4-hour thrice weekly in center hemodialysis, 8-hour thrice weekly in center hemodialysis
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 410 people
- Sponsor
- Ege University
End Stage Renal Disease, Left Ventricular Hypertrophy
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Kidney patients on dialysis commonly die because of heart disease. One of the biggest problems in their hearts is that the muscle wall of the heart thickens. This makes it less efficient.
- Trial name
- Altered (NCT01951404)
- Testing
- Allopurinol
- Where
- 3 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Dundee
End Stage Heart Failure
Impact of LVAD Implantation on Micro- and Macrovascular Function
End stage heart failure is characterized by a critical inability of the heart to meet the organism's blood demand even under resting conditions.
- Trial name
- LVAD (NCT02174133)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Klinik für Kardiologie, Pneumologie und Angiologie
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy
Use of Beta-agonists in Stable Severe Congestive Heart Failure
The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure
- Trial name
- NCT01447069
- Testing
- Salbutamol
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Chronic Kidney Diseases, Heart Failure
REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.
The is a non-randomized pilot trial, open-label evaluation of the physiologic response of native kidney denervation using the Paradise denervation system in CKD, End Stage Renal Disease (ESRD), and Heart failure (HF)
- Conditions
- Chronic Kidney Diseases, Heart Failure, End Stage Renal Disease
- Trial name
- RESURRECT (NCT05703620)
- Testing
- Renal Denervation
- Where
- Australia
- Volunteers
- 75 people
- Sponsor
- Royal Perth Hospital
Severe Life-limiting COPD, Severe Life-limiting Heart Failure
Communication During Hospitalization About Resuscitation Trial
This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients…
- Conditions
- Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy
- Trial name
- CHART (NCT02984124)
- Testing
- Informed Assent Discussion, Usual Care with Attention Control
- Where
- 4 sites in United States
- Volunteers
- 182 people
- Sponsor
- University of Vermont